Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akorn AKRXQ

Healthcare Drug Manufacturers - Major
Akorn Inc is a pharmaceutical company. It is engaged in the development, manufacturing, and marketing of generic and prescription pharmaceuticals. The firm has two segments namely Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals including sterile ophthalmics, injectables, and inhalants, and... see more

Recent & Breaking News (OTCPK:AKRXQ)

Akorn Outlines Timeline for 2015 Form 10-K Filing, First Quarter 2016 Form 10-Q Filing and Investor Conference Calls

GlobeNewswire May 6, 2016

Akorn Provides Preliminary Unaudited Full Year 2015 Financial Results and Issues 2016 Financial Guidance

GlobeNewswire March 22, 2016

Akorn Receives Expected Additional Delinquency Notice From Nasdaq

GlobeNewswire March 7, 2016

Akorn Announces Conference Call to Provide Business Updates; Partial Prepayment of Term Loan Facility

GlobeNewswire February 25, 2016

Akorn Announces Conclusion of Audit Committee Independent Investigation

GlobeNewswire January 27, 2016

Akorn Appoints Greg Lawless as Chief Human Resources Officer

GlobeNewswire January 21, 2016

Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection

GlobeNewswire January 19, 2016

Akorn Provides Material Updates

GlobeNewswire January 14, 2016

Akorn Receives Additional Delinquency Notice from Nasdaq

GlobeNewswire November 13, 2015

Akorn Provides Business and Financial Guidance Update

GlobeNewswire November 4, 2015

Akorn Provides Update on Alternative Fulfillment Systems

GlobeNewswire October 21, 2015

Akorn Appoints Duane A. Portwood as Chief Financial Officer

GlobeNewswire October 13, 2015

Akorn Launches Myorisan(TM) 30 mg Capsules

GlobeNewswire September 28, 2015

Akorn Launches Doxercalciferol Injection

GlobeNewswire September 21, 2015

Akorn Launches Two Additional Promethazine Syrup Formulations

GlobeNewswire September 17, 2015

Akorn Receives NASDAQ Delinquency Notice

GlobeNewswire August 14, 2015

Block & Leviton LLP Investigates Akorn, Inc. for Possible Violations of the Federal Securities Laws

PR Newswire August 11, 2015

Akorn Appoints Randy Pollard as Interim Chief Financial Officer

GlobeNewswire August 4, 2015

The Law Firm of Morgan & Morgan Is Investigating Possible Breaches of Fiduciary Duty At Akorn Inc. Regarding AKRX

PR Newswire July 29, 2015

Akorn Announces Nasdaq's Acceptance of Its Plan to Regain Compliance

GlobeNewswire July 15, 2015